Welcome to our dedicated page for Xeris Biopharma Holdings news (Ticker: XERS), a resource for investors and traders seeking the latest updates and insights on Xeris Biopharma Holdings stock.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) is a biopharmaceutical company headquartered in Chicago, Illinois, with a commercial portfolio and pipeline focused on endocrine and neurological conditions. News about Xeris frequently centers on the performance of its three marketed products—Recorlev, Gvoke, and Keveyis—as well as updates on its lead pipeline candidate, XP-8121, and its proprietary XeriSol and XeriJect formulation platforms.
Investors following XERS news can expect regular coverage of quarterly and full-year financial results, including product-level revenue for Recorlev, Gvoke, and Keveyis, trends in patient demand, and commentary on profitability metrics such as Adjusted EBITDA. The company’s press releases and accompanying Form 8-K filings provide detailed breakdowns of revenue, costs, and operating performance, along with management’s discussion of strategic priorities.
Xeris news flow also includes announcements related to intellectual property, such as Orange Book listings and patent notices for Recorlev and XP-8121, as well as partnership updates like the agreement with American Regent for the commercialization of Gvoke VialDx in the United States. Additional items may cover analyst and investor events, revenue guidance updates, and long-term outlooks that management shares with the market.
For those tracking developments in Xeris’ pipeline, news items highlight regulatory milestones, patent allowances, and R&D investment in XP-8121 and other early-stage programs using XeriSol and XeriJect. By monitoring this news page, readers can review a chronological record of Xeris’ operational, financial, and strategic announcements as they are released.
Xeris (Nasdaq: XERS) announced unaudited preliminary results for FY2025 and Q4, expecting $292 million in total 2025 revenue, above prior guidance of $285–$290 million and representing 44% growth year-over-year. The company expects Recorlev net revenue of $45 million in Q4 and $139 million for full-year 2025. Recorlev ended the year with ~700 patients on therapy. Gvoke revenue grew >13% versus prior year and Keveyis patient numbers increased versus 2024. Xeris reported positive Adjusted EBITDA in every quarter, strengthened IP with a new Orange Book-listed U.S. patent for Recorlev and a composition-of-matter patent for XP-8121, and plans to release full FY2025 results and 2026 outlook on March 2, 2026.
Xeris Pharmaceuticals (Nasdaq: XERS) announced that on January 2, 2026 its Compensation Committee granted 181,550 restricted stock units to 50 new employees under the company's Inducement Equity Plan pursuant to NASDAQ Rule 5635(c)(4).
The RSUs vest in equal annual installments over three years and are subject to continued employment and the plan's award agreement terms.
Xeris (Nasdaq: XERS) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a U.S. patent application covering XP-8121, a novel levothyroxine (LT4) formulation candidate. The Notice indicates the application meets patentability requirements and is expected to issue as a U.S. patent after standard administrative steps. The allowed claims are specific to the XP-8121 formulation. Xeris said it will continue pursuing additional U.S. and international intellectual property layers for its LT4 technology and highlighted the XeriSol platform's role in enabling subcutaneous formulations.
Xeris (NASDAQ: XERS) reported record third-quarter 2025 results, with total product revenue up 40% YoY to $74.1M and total revenue $74.4M. Recorlev revenue rose ~109% to $37.0M, driving growth across the portfolio. The company updated 2025 total revenue guidance to $285–$290M, implying ~42% growth at the midpoint versus 2024. Adjusted EBITDA improved to $17.4M in Q3; Q3 net income was $0.6M versus a prior-year loss. Management noted continued investment in R&D and commercial expansion while hosting a conference call and investor events.
Xeris Biopharma (NASDAQ: XERS) will release its third quarter 2025 financial results before U.S. market open on Thursday, November 6, 2025. Management will host a conference call and webcast at 8:30 a.m. Eastern Time the same day to discuss financial and operational results.
Investors are encouraged to pre-register for the call; registrants receive a confirmation email with dial-in details and a unique entry code. A replay will be available through Thursday, November 20, 2025 using the provided international and toll-free numbers and access code 606180. The live webcast and archived materials will be posted in the Events section of Xeris’ investor relations website.
Xeris (Nasdaq: XERS) announced on October 1, 2025 that its Compensation Committee granted 382,975 restricted stock units to 40 new employees under the company's Inducement Equity Plan pursuant to Nasdaq Rule 5635(c)(4).
The RSUs vest in equal annual installments over three years and are conditioned on continued employment. All awards are subject to the Inducement Equity Plan terms and award agreements.
Xeris Pharmaceuticals (NASDAQ:XERS) announced the commercial launch of Gvoke VialDx™ (glucagon injection) through its partnership with American Regent. This marks a significant milestone as the first concentrated, ready-to-dilute liquid glucagon available for diagnostic procedures.
The product is indicated for intravenous use as a diagnostic aid during radiologic examinations to temporarily inhibit gastrointestinal tract movement in adult patients. Gvoke VialDx will be available in 1-count or 10-count packages of 1 mg per 0.2 mL single-dose vials and is ready for immediate shipment. Under the partnership agreement, Xeris will handle product supply while American Regent manages U.S. commercialization.
Xeris Biopharma (Nasdaq: XERS) has strengthened its intellectual property portfolio with a new U.S. patent for Recorlev® (levoketoconazole), now listed in the FDA's Orange Book. The patent (No. 12,377,096) covers therapeutic uses that minimize drug-drug interactions between levoketoconazole and MATE1 substrates, extending protection until March 2040.
Recorlev, approved by the FDA in December 2021 for treating endogenous Cushing's syndrome in adult patients where surgery isn't an option, now holds four Orange Book-listed patents. The drug represents a significant advancement for patients with this rare endocrine disease, with Xeris continuing to invest in education, patient support, and market access initiatives.
Xeris Biopharma (Nasdaq: XERS) reported exceptional Q2 2025 financial results, with total revenue surging 49% year-over-year to $71.5 million. The company's flagship product Recorlev® led growth with a 136% YoY increase to $31.4 million, driven by a 122% rise in patient numbers. Gvoke® revenue grew 17% to $23.5 million, while Keveyis® declined 13% to $11.5 million.
The company significantly improved its bottom line, reducing net loss by 87% to $1.9 million ($0.01 per share) and achieving positive Adjusted EBITDA of $12.5 million. Based on strong performance, Xeris raised its full-year 2025 revenue guidance to $280-290 million from $260-275 million previously. The company also outlined ambitious long-term targets, including $750 million in total revenue by 2030 and nearly $1 billion in Recorlev net revenue by 2035.
Xeris Biopharma (Nasdaq: XERS), a growing biopharmaceutical company, will release its second quarter 2025 financial results on Thursday, August 7, 2025, before U.S. markets open.
The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss financial and operational results. A replay will be available until August 21, 2025 through various dial-in numbers. Investors can access the webcast through the company's investor relations website.
FAQ
What is the current stock price of Xeris Biopharma Holdings (XERS)?
What is the market cap of Xeris Biopharma Holdings (XERS)?
